“Were Women Studied?” audit
Fracture Prevention Trial (NCT00670501) and related osteoporosis trials
Teriparatide osteoporosis trials included large numbers of postmenopausal women; sex-comparative analysis is not applicable to these women-only cohorts.
Representation grade
Target population represented
Sex-analysis grade
No interpretable sex analysis
Target population represented with useful denominator detail
Basis: The pivotal fracture trial enrolled 1,637 postmenopausal women with osteoporosis.
Women included but no interpretable sex analysis
Population and enrollment
Enrollment breakdown
Terminology in source: Sex; women-only cohorts.
0%
women / female participants
0 of 0 enrolled
Inclusion and exclusion by life stage
Sex-analysis plan and findings
Missing data and generalizability limits
Data in younger women, premenopausal osteoporosis, and male osteoporosis are reported separately.
Findings apply to postmenopausal women with the studied fracture-risk profile.
Sources
Primary records
- regulatory label
Gateway to current FDA-approved prescribing information. Confirm the exact product label before clinical use.
- peer reviewed article
Index of peer-reviewed biomedical literature.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.